Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
· mineralys therapeutics, inc.
AI Briefing
- Mineralys Therapeutics receives FDA acceptance of NDA for Lorundrostat
- Lorundrostat aims to treat adults with hypertension and OSA
- PDUFA target action date set for December 22, 2026
Advertisement